Scorpius Holdings, INC 8-K filings

OTC.Pink
Scorpius Holdings, Inc. has entered into a $600,000 promissory note agreement and engaged Alliance Global Partners to explore strategic alternatives.
OTC.Pink
Scorpius Holdings, Inc. amended its senior secured convertible notes and common stock purchase warrants, lowering the conversion and exercise prices to $0.25 per share.
OTC.Pink
Scorpius Holdings, Inc. secures $1 million in funding through a non-convertible promissory note issued to 3i, L.P., bearing a 5% interest rate and maturing by April 30, 2025, or earlier upon a corporate event or default.
OTC.Pink
Scorpius Holdings, Inc. secures $600,000 in funding through a non-convertible promissory note with an institutional investor, bearing a 5% interest rate and maturing by March 31, 2025, or upon a corporate event.
OTC.Pink
Scorpius Holdings has announced that it will not proceed with the previously announced 1-for-20 reverse stock split of its common stock.
OTC.Pink
Scorpius Holdings has approved a 1-for-20 reverse stock split to increase its share price and maintain compliance with NYSE American listing requirements.
OTC.Pink
Scorpius Holdings is facing a critical need for additional financing within the next month and warns of potential operational disruptions if funding is not secured.
OTC.Pink
Scorpius Holdings has entered into a securities purchase agreement for a $12 million private placement of senior secured convertible notes and warrants.
OTC.Pink
Scorpius Holdings Inc. has issued a $225,000 non-convertible promissory note to an institutional investor with a 5% interest rate, maturing on December 15, 2024, or upon a corporate event or default.
OTC.Pink
Scorpius Holdings announced a 142% year-over-year revenue increase for the nine months ended September 30, 2024, alongside a 23.5% reduction in operating expenses.
OTC.Pink
Scorpius Holdings has amended the employment agreements of its CEO and CFO to include performance-based bonuses tied to new client bookings through the end of 2024.
OTC.Pink
Scorpius Holdings, Inc. has announced the pricing of a $12.5 million underwritten public offering, with shares and pre-funded warrants set at $1.00 each, aiming to bolster working capital and support general corporate activities.
OTC.Pink
Scorpius Holdings plans a public offering of 12.5 million shares at $1.00 per share, utilizing a financial viability exception from NYSE American shareholder approval rules after an initial underwriting agreement was terminated.
OTC.Pink
Scorpius Holdings anticipates revenue between $0.3 million and $0.8 million for the second quarter of 2024, with operating and net losses expected to be between $8.6 million and $9.7 million.
OTC.Pink
Scorpius Holdings has cancelled a $750,000 promissory note in exchange for a $2.5 million cash payment and the elimination of royalty fees in an amended agreement with Elusys Holdings.
OTC.Pink
Scorpius Holdings' common stock is set to resume trading on the NYSE American on August 2, 2024, after the exchange withdrew its delisting determination.
OTC.Pink
Scorpius Holdings has amended a promissory note, extending its maturity date and securing it with a subordinated lien on company assets, while also implementing a 1-for-200 reverse stock split to regain compliance with NYSE American listing requirements.
OTC.Pink
Scorpius Holdings, Inc. has received notice of delisting from the NYSE American due to its low stock price and will begin trading on the OTC Markets system on June 17, 2024.
OTC.Pink
Scorpius Holdings has regained compliance with NYSE listing standards after filing its delayed Q1 2024 report and has rescheduled its annual meeting for July 19, 2024.
OTC.Pink
Scorpius Holdings, Inc. reported a significant 359% year-over-year increase in revenue for the first quarter of 2024, accompanied by a 34% reduction in operating expenses.
OTC.Pink
Scorpius Holdings has received a notice from the NYSE American LLC for failing to file its quarterly report, putting the company at risk of delisting.
OTC.Pink
Scorpius Holdings, Inc. announced that it has 96,281,964 outstanding shares of common stock as of May 21, 2024.
OTC.Pink
Scorpius Holdings, Inc. has successfully closed a public offering, raising approximately $6 million through the sale of common and pre-funded units, each including warrants.
OTC.Pink
Scorpius Holdings anticipates revenue between $4.0 million and $5.0 million for the first quarter of 2024, with operating and net losses also expected.
OTC.Pink
Scorpius Holdings has entered into a note purchase agreement for a $750,000 loan and restructured a prior convertible note, extending its maturity and adjusting conversion terms.
OTC.Pink
Scorpius Holdings has regained compliance with NYSE American listing standards after filing its overdue 2023 annual report.
OTC.Pink
Scorpius Holdings announced a significant 570% sequential increase in revenue for the fourth quarter of 2023, alongside strategic updates and a positive outlook for future growth.
OTC.Pink
Scorpius Holdings received a notice from the NYSE American for failing to file its annual report on time, potentially leading to delisting.
OTC.Pink
Scorpius Holdings has extended its stockholder rights plan to March 11, 2025, and closed a public offering of 10 million shares at $0.15 per share, raising $1.5 million.
OTC.Pink
Scorpius Holdings, Inc. has announced an underwritten public offering to sell 10,000,000 shares of its common stock, expected to raise $1.5 million in gross proceeds.